Skip to main content
Top

Open Access 20-11-2023 | Pharmacokinetics | Original Research Article

Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers

Authors: Maodi Xu, Yaqin Wang, Xiaohu Wang, Zhichen Pu, Ya Liu, Cuilian Jiang, Xiaokun Shen, Hua Sun, Haitang Xie

Published in: Drugs in R&D

Login to get access

Abstract

Introduction

Glucokinase (GK) plays a pivotal role in maintaining glucose homeostasis; globalagliatin, a newly developed drug, is a GK activator (GKA). This study constitutes a randomized, open-label, two-cycle, two-crossover, single-dose, phase I clinical trial conducted at a single center with healthy Chinese volunteers, aiming to examine the influence of a high-fat meal on the pharmacokinetics (PK) of orally administered globalagliatin.

Methods

Twenty-four healthy volunteers were randomly divided into two groups, with a washout period of 16 days between the two cycles. The first cycle involved Group 1 volunteers who were orally administered globalagliatin 80 mg with 240 mL of water while fasting on Day 1. In contrast, Group 2 volunteers began oral administration of globalagliatin 80 mg with 240 mL of water, 30 min after consuming a high-fat meal (where high-fat content contributed to 54% of the total calories; the high-calorie meal amounted to 988.4 kcal). After the washout period, both groups of volunteers entered the second cycle of drug administration, with meals and medication being swapped on Day 17. Each volunteer collected blood samples at the following time points: 0 h (within 1 h before administration), and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, and 168 h after administration on both trial Day 1 and Day 17. The primary and secondary PK parameters were collected. The validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used to determine the concentration of globalagliatin in collected plasma samples, and the results were analyzed using Phoenix WinNonlin software. Safety evaluation was conducted by detecting or observing various adverse events (AEs) and serious AEs (SAEs).

Results

All 24 healthy Chinese volunteers enrolled completed the study and underwent PK analysis. The maximum concentration (Cmax; ng/mL), area under the plasma concentration-time curve (AUC) from time zero to time of the last quantifiable concentration (AUCt; h·ng/mL), and AUC from time zero extrapolated to infinity (AUC; h·ng/mL) of fasting administration were 22.35 ± 7.02, 725.74 ± 303.04, and 774.07 ± 343.89, respectively, while the Cmax, AUCt, and AUC administered after a high-fat meal were 28.95 ± 12.60, 964.84 ± 333.99, and 1031.28 ± 392.80, respectively. The geometric mean ratios of Cmax, AUCt, and AUC for high-fat meal/fasting administration of globalagliatin were 124.81%, 135.24%, and 135.42%, respectively, with 90% confidence intervals of 109.97–141.65, 124.24–147.20, and 124.42–147.39, respectively. Compared with the fasting state, healthy volunteers who consumed a high-fat meal showed a 24.8% increase in Cmax, a 35.2% increase in AUCt, and a 35.4% increase in AUC. The geometric mean of Tmax was 4.69 h under fasting conditions and 5.93 h in a high-fat state, with a median of 4.98 h. Among the 24 enrolled volunteers, 9 cases (37.5%) had 11 AEs, and 6 cases (25.0%) had 7 adverse drug reactions (ADRs) after medication, all of which were cured or improved without taking any treatment measures. There were no SAEs in this study, no volunteers withdrew from the study due to AEs or ADRs, and no hypoglycemic events occurred during the trial.

Conclusion

A high-fat meal increased the Cmax, AUCt, and AUC of globalagliatin compared with fasting conditions in healthy Chinese adult volunteers. Meanwhile, globalagliatin showed favorable safety and tolerability under fasting or high-fat meal conditions.
Literature
1.
go back to reference Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108086.CrossRefPubMed Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108086.CrossRefPubMed
2.
go back to reference American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes–2021. Diabetes Care. 2021;44(Suppl 1):S15–33.CrossRef American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes–2021. Diabetes Care. 2021;44(Suppl 1):S15–33.CrossRef
3.
go back to reference Chen Q, Zhu L, Tang Y, et al. Preparation-related structural diversity and medical potential in the treatment of diabetes mellitus with ginseng pectins. Ann N Y Acad Sci. 2017;1401(1):75–89.CrossRefPubMed Chen Q, Zhu L, Tang Y, et al. Preparation-related structural diversity and medical potential in the treatment of diabetes mellitus with ginseng pectins. Ann N Y Acad Sci. 2017;1401(1):75–89.CrossRefPubMed
4.
go back to reference Diabetes Society of Chinese Medical Association. Guidelines for the Prevention and Treatment of Type 2 diabetes in China (2020 edition). Chin J Diabetes. 2021;13(4):315–409. Diabetes Society of Chinese Medical Association. Guidelines for the Prevention and Treatment of Type 2 diabetes in China (2020 edition). Chin J Diabetes. 2021;13(4):315–409.
5.
go back to reference Sharma P, Singh S, Thakur V, et al. Novel and emerging therapeutic drug targets for management of type 2 diabetes mellitus. Obesity Med. 2021;23: 100329.CrossRef Sharma P, Singh S, Thakur V, et al. Novel and emerging therapeutic drug targets for management of type 2 diabetes mellitus. Obesity Med. 2021;23: 100329.CrossRef
6.
go back to reference Herrera JJ, Louzon S, Pifer K, et al. Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology. JCI Insight. 2020;5(21): e137474.CrossRefPubMedPubMedCentral Herrera JJ, Louzon S, Pifer K, et al. Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology. JCI Insight. 2020;5(21): e137474.CrossRefPubMedPubMedCentral
7.
go back to reference Zhu D, Gan S, Liu Y, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018;6(8):627–36.CrossRefPubMed Zhu D, Gan S, Liu Y, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018;6(8):627–36.CrossRefPubMed
8.
go back to reference Zhu XX, Zhu DL, Li XY, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic beta-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab. 2018;20(9):2113–20.CrossRefPubMed Zhu XX, Zhu DL, Li XY, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic beta-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab. 2018;20(9):2113–20.CrossRefPubMed
9.
go back to reference Zhao Y, Xie L, Zhang H, et al. Tolerability, safety, pharmacokinetics, and pharmacodynamics of SY-004, a glucokinase activator, in healthy Chinese adults: a randomized, phase Ia. Single-Ascending Dose Study Clin Ther. 2022;44(2):269–81.PubMed Zhao Y, Xie L, Zhang H, et al. Tolerability, safety, pharmacokinetics, and pharmacodynamics of SY-004, a glucokinase activator, in healthy Chinese adults: a randomized, phase Ia. Single-Ascending Dose Study Clin Ther. 2022;44(2):269–81.PubMed
10.
go back to reference Zheng S, Shao F, Ding Y, et al. Safety, pharmacokinetics, and pharmacodynamics of globalagliatin, a glucokinase activator, in chinese patients with type 2 diabetes mellitus: a randomized, phase Ib, 28-day ascending dose study. Clin Drug Investig. 2020;40(12):1155–66.CrossRefPubMed Zheng S, Shao F, Ding Y, et al. Safety, pharmacokinetics, and pharmacodynamics of globalagliatin, a glucokinase activator, in chinese patients with type 2 diabetes mellitus: a randomized, phase Ib, 28-day ascending dose study. Clin Drug Investig. 2020;40(12):1155–66.CrossRefPubMed
11.
go back to reference Cheng L, Wong H. Food Effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool. Pharmaceutics. 2020;12(7):672.CrossRefPubMedPubMedCentral Cheng L, Wong H. Food Effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool. Pharmaceutics. 2020;12(7):672.CrossRefPubMedPubMedCentral
12.
go back to reference Tistaert C, Heimbach T, Xia B, et al. Food effect projections via physiologically based pharmacokinetic modeling: predictive case studies. J Pharm Sci. 2019;108(1):592–602.CrossRefPubMed Tistaert C, Heimbach T, Xia B, et al. Food effect projections via physiologically based pharmacokinetic modeling: predictive case studies. J Pharm Sci. 2019;108(1):592–602.CrossRefPubMed
16.
go back to reference Ren Y, Li L, Wan L, Huang Y, Cao S. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists. J Enzyme Inhib Med Chem. 2022;37:606–15.CrossRefPubMedPubMedCentral Ren Y, Li L, Wan L, Huang Y, Cao S. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists. J Enzyme Inhib Med Chem. 2022;37:606–15.CrossRefPubMedPubMedCentral
17.
go back to reference Kiyosue A, Hayashi N, Komori H, et al. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:923–30.CrossRefPubMed Kiyosue A, Hayashi N, Komori H, et al. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:923–30.CrossRefPubMed
18.
go back to reference Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2560–6.CrossRefPubMedPubMedCentral Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2560–6.CrossRefPubMedPubMedCentral
19.
go back to reference Amin NB, Aggarwal N, Pall D, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015;17:751–9.CrossRefPubMed Amin NB, Aggarwal N, Pall D, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015;17:751–9.CrossRefPubMed
20.
go back to reference Zhu D, Gan S, Liu Y, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018;6:627–36.CrossRefPubMed Zhu D, Gan S, Liu Y, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018;6:627–36.CrossRefPubMed
21.
go back to reference Liu Yan-Ping Hu, Ming-Hui L-P, et al. Evaluation of the effect of food on the pharmacokinetics of SHR6390, an oral CDK4/6 inhibitor, in healthy volunteers. Drugs RD. 2022;22:175–82.CrossRef Liu Yan-Ping Hu, Ming-Hui L-P, et al. Evaluation of the effect of food on the pharmacokinetics of SHR6390, an oral CDK4/6 inhibitor, in healthy volunteers. Drugs RD. 2022;22:175–82.CrossRef
22.
go back to reference Tugnait M, Gupta N, Hanley MJ, et al. The effect of a high-fat meal on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8:734–41.CrossRefPubMed Tugnait M, Gupta N, Hanley MJ, et al. The effect of a high-fat meal on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8:734–41.CrossRefPubMed
23.
go back to reference Toulis KA, Nirantharakumar K, Pourzitaki C, et al. Glucokinase activators for type 2 diabetes: challenges and future developments. Drugs. 2020;80:467–75.CrossRefPubMed Toulis KA, Nirantharakumar K, Pourzitaki C, et al. Glucokinase activators for type 2 diabetes: challenges and future developments. Drugs. 2020;80:467–75.CrossRefPubMed
24.
go back to reference Katz L, Manamley N, Snyder WJ, et al. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:191–5.CrossRefPubMed Katz L, Manamley N, Snyder WJ, et al. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:191–5.CrossRefPubMed
Metadata
Title
Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers
Authors
Maodi Xu
Yaqin Wang
Xiaohu Wang
Zhichen Pu
Ya Liu
Cuilian Jiang
Xiaokun Shen
Hua Sun
Haitang Xie
Publication date
20-11-2023
Publisher
Springer International Publishing
Published in
Drugs in R&D
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI
https://doi.org/10.1007/s40268-023-00448-0